As of June 12, 2025, Protara Therapeutics Inc (TARA) reports a Net Margin of -113.22%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Comparing Protara Therapeutics Inc's Net Margin to Peers
To better understand Protara Therapeutics Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Protara Therapeutics Inc (TARA) | -113.22% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
| Fennec Pharmaceuticals Inc (FENC) | -0.92% |
Compared to its competitors, Protara Therapeutics Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.